A Massachusetts District Court this week denied motions to dismiss an intellectual property-ownership lawsuit filed by the University of Utah against Alnylam Pharmaceuticals and several University of Massachusetts officials, among others, telling the defendants that they have not provided sufficient reasons why the litigation should be halted.

As a result, the dispute over whether University of Utah researcher Brenda Bass should be named as an inventor of a key RNAi technology, along with several Alnylam co-founders, will proceed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.